Implications for atypical antipsychotics in the treatment of schizophrenia: Neurocognition effects and a neuroprotective hypothesis

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1759-1783

  Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Cognition; Schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR; ANTICONVULSIVE AGENT; APOLIPOPROTEIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIZOCILPINE; FLUOXETINE; HALOPERIDOL; LEVODOPA; LITHIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTENSIN; OLANZAPINE; PHYSOSTIGMINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; VALPROIC ACID; ZIPRASIDONE;

ALLELE; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; APOPTOSIS; ATTENTION; BIOCHEMISTRY; BRAIN DEVELOPMENT; BRAIN REGION; CELL CULTURE; CELL DENSITY; CELL STRAIN; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CORRELATION ANALYSIS; DELUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HALLUCINATION; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; INTELLIGENCE QUOTIENT; INTELLIGENCE TEST; LEARNING; LOW DRUG DOSE; MEMORY; MENTAL PERFORMANCE; MOTOR COORDINATION; NEGATIVE SYNDROME; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERSONALITY TEST; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROBLEM SOLVING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; RECEPTOR AFFINITY; RECOGNITION; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; SEDATION; SYMPTOM; SYMPTOMATOLOGY; TASK PERFORMANCE; TREATMENT OUTCOME; VERBAL BEHAVIOR; WISCONSIN CARD SORTING TEST; WORKING MEMORY; XEROSTOMIA;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; CATECHOL O-METHYLTRANSFERASE; COGNITION; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; NEUROPROTECTIVE AGENTS; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 9644278029     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1759.52346     Document Type: Review

References (87)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. Stahl SM, ed. Psychosis and schizophrenia. In: Essential psychopharmacology of antipsychotics and mood stabilizers. New York: Cambridge University Press, 2002:1-37.
3. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on the pathogenesis, pathophysiology and therapeutic approaches. Biol Psychiatry 2001;50:884-97.
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
5. Nemeroff CB. New perspectives on the neurobiology of schizophrenia and the role of atypical antipsychotics. Biol Psychiatry 2001;50:823-4.
6. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003;3:27-39.
7. Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St. George-Hyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 2003;302:822-6.
8. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001;58:148-57.
9. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
10. Weiss AP, Schacter, DL, Goff DC, et al. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry 2003;53:48-55.
11. PerIstein WM, Dixie NK, Carter CS, Noll DC, Cohen JD. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003;53:25-38.
12. Fannon D, Simmons A, Tennakoon L, et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol Psychiatry 2003;54:587-98.
13. Stanley JA, Williamson PC, Drost DJ, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995;52:399-406.
14. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44.
15. Malhotia AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-4.
16. 158 Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701-7.
17. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83.
18. Goff DC, Coyle JT. Glutamate in schizophrenia: clinical and research implications. Schizophrenia Res 1997;27:157-68.
19. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;12:21-36.
20. 2 receptors as potential pharmacotherapy for schizophrenia. II. Glutamate (ant)agonists. Ann Pharmacother 2000;34:788-97.
21. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.
22. Leveque JC, Macias W, Rajadhyaksha A, et al. Intracellular modulation of NMD receptor function by antipsychotic drugs. J Neurosci 2000;20:4011-20.
23. Tarzi FI. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003;306:1145-51.
24. Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 2003;17:57-68.
25. Terrisse L, Poirier J, Bertrand P, et al. Increased levels of apolipoprotein D in CSF and hippocampus of Alzheimer's patients. J Neurochem 1998;71:1643-50.
26. Thomas EA, Sautkulis LN, Criado JR, Gomes D, Sutcliff JG. Apolipoprotein D in RNA expression is elevated in PDAPP transgenic mice. J Neurochem 2001;79:1059-64.
27. Thomas EA, Dean B, Pavey G, Sutcliff JG. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar patients: implications for the pathophysiology of psychiatric disorders. Proc Natl Acad Sci U S A 2001;98:4066-71.
28. Thomas EA, Laws SM, Sutcliff JG, et al. Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relations to apolipoprotein E expression or genotype. Biol Psychiatry 2003;54:136-41.
29. Khan MM, Parikh VV, Mahadik SP. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. J Neurochem 2003;86:1089-100.
30. Mahadik SP, Khan MM, Evans D, Parikh W. Elevated plasma levels of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophrenia Res 2002;58:55-62.
31. Dean B, Laws SM, Hone E, et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 2003;54:616-22.
32. Terry AV, Buccasfusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:621-7.
33. Terry AV, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology 2002;164:360-8.
34. Terry AV, Hill WD, Parikh V, Waller JL, Evans DR, Mahadik SP. Differential effect of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 2003;28:300-9.
35. Nemeroff CB, Luttinger D, Hernandez DE, et al. Interactions of neurotensin and brain dopamine systems: biochemical and behavioral studies. J Pharmacol Exp Ther 1983;225:337-45.
36. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001;50:856-72.
37. 2 receptors as a major mechanism for neuroleptic-like action of neurotensin. Ann N Y Acad Sci 1992;668:186-204.
38. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296:1635-6,
39. Lewis R. Deciphering death's circuitry. Scientist 2003;3:32-3.
40. Finkel E. The mitochondrion: is it central to apoptosis? Science 2003;292:624-6.
41. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bel-2 promotes regeneration of severed axons in mammalia CNS. Nature 1997;385:434-9.
42. Jarskog LF, Gilmore JH, Selinger ES, Liberman JA. Cortical Bel-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 2000;48:641-50.
43. Hall SS. The quest for the smart pill. Sci Am 2003;289:54-65.
44. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotropics factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-31.
45. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002;321:65-8.
46. Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM. Chronic elevation of brain-derived neurotropic factor by ampakines. J Pharmacol Exp Ther 2003;307:297-305.
47. Vaudry D, Strok PJS, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation: making the right connections. Science 2002;296:1648-9.
48. Li XM, Chlan-Fourney J, Juorio AV, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 1999;56:72-5.
49. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002;69:278-83.
50. Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003;73:364-8.
51. Parikh V, Khan M, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatric Res 2003;37:43-51.
52. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs haloperidol to protect PC12 cells against MPP+ induced apoptosis. Eur J Neurosci 2003;17:1563-70.
53. Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002;69:72-9.
54. Parikh V, Evans DR, Khan M, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophrenia Res 2003;60:117-23.
55. Rohlff C, Hollis K. Modern proteomic strategies in the study of simplex neuropsychiatrie disorders. Biol Psychiatry 2003;53:847-53.
56. Muly EC. Signal transduction abnormalities in schizophrenia: the cAMP system. Psychopharmacol Bull 2002;36:92-105.
57. Kyosseva S, Elbein A, Hutton TL, et al. Increased levels of transcription factors Elk-1, cyclic monophosphate response element-binding protein and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. Arch Gen Psychiatry 2000;57:685-91.
58. 1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor Ser897-NR1. J Neurochem 2003;87:922-34.
59. Svenningsson P, Tzavara ET, Carruthors R, et al. Diverse psychotomimetics act through a common signaling pathway. Science 2003;302:1412-15.
60. Laughlin SB, Sejnowski TJ. Communication in neuronal networks. Science 2003;301:1870-4.
61. Paulis MP, Braff DL. Chaos and schizophrenia: does the method fit the madness? Biol Psychiatry 2003;53:3-11.
62. Kraepelin E, Barclay RM, Robertson GM. Dementia praecox and paraphrenia. Edinburgh, Scotland: E&S Livingstone, 1919.
63. Purdon SE. Cognition improvement in schizophrenia with novel antipsychotic medications. Schizophrenia Res 1999;35:S51-60.
64. Lezak MD. Neuropsychological assessment. New York: Oxford University Press, 1976.
65. Guy WG. ECDEU assessment manual for psychopharmacology, revised. Department of Health and Human Services, publication no. 91-338. Washington, DC: Department of Health and Human Services, 1976.
66. Stip E, Remington GJ, Durson SM, et al. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 2003;23:400-4.
67. Weickert TW, Goldbert TE, Marenco S, Biglow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003;28:1491-500.
68. Potkin SG, Fleming K, Jin Y, Giulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-83.
69. Schuebach D, Keshavan MS, Kmiec JA, Sweeny JA. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophrenia Res 2002;53:249-61.
70. Purdon SE, Woodward N, Lindborg SR, Step E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone and haloperidol. Psychopharmacology 2003;169:390-7.
71. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
72. Green Mf, Marder SR, Glynn SM, et al. The neurocognitive effects of low dose haloperidol: a two year comparison with risperidone. Biol Psychiatry 2002;52:972-8.
73. Heltzer HY, Lee MA. Quetiapine improves cognitive function in schizophrenia. Presented at the annual meeting of the American Psychiatric Association, New Orleans, LA, May 5-10, 2001.
74. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Res 2002;53:239-48.
75. Cornblatt B, Carson WH, Ali M, Kern RS, Luo X, Green M. Neurocognitive effects of aripiprazole vs olanzapine [abstr]. Int J Neuropsychopharmacol 2002;5(suppl 1):S185.
76. Harvery PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone in outpatients with schizophrenia. Schizophrenia Res 2004;66:101-13.
77. Harvey PD, Napolitan JA, Mao L, Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 2003;18:820-8.
78. Freidman JI, Temprini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-16.
79. Lenzl A, Maltini E, Poggi E, Fabrizo L, Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 2003;26:317-21.
80. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mosbius HJ, for the Memantine Study Group. Memantine in moderate to severe Alzheimer's disease. N EnglJ Med 2003;348:1333-41.
81. Goff DC, Leahy L, Herman I, et al. A placebo-controlled pilot study of the ampakine CX 516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21:484-7.
82. Koechlin E, Ody C, Kouneiher F. The architecture of cognitive control in the human prefrontal cortex. Science 2003;302:1181-5.
83. Javih DC, Coyle JT. Decoding schizophrenia. Sci Am 2004;290:48-55.
84. Manji H. Depression III [editorial]. Am J Psychiatry 2003;160:24.
85. Carpenter WT. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 2002;52:969-71.
86. Woods SW, Brier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003;54:453-64.
87. Stock EG, Archibald DG, Tourkodimitrious S, Kujawa MJ, Marcus R, Carson WH. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.